Enzymatic Therapy strategy
This article was originally published in The Tan Sheet
Executive Summary
Only about 1% of 1,044 structure/function claims submitted in the past year have been cited in FDA "courtesy" letters, according to Green Bay, Wisc.-based firm, which notes its strategy is to "submit claims we have no serious intention of using...to help us better understand FDA's interpretation of the law." Approach accounts for firm's receipt of roughly 18 "courtesy" letters in past year, as reported in 1"The Tan Sheet" May 27, 2002, p. 7...
You may also be interested in...
“Dry Throat” Not A Disease, “Soothe” A Cosmetic Claim, Tom’s Of Maine Says
Tom's of Maine may not claim its eponymous Natural Bronchial Syrup for Children and Natural Bronchial Syrup for Adults "sooth[es] dry throat," FDA says in a recent "courtesy" letter
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.